Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective

Pneumonia

Table 4 The median treatment costs, treatment periods, and mortality rates according to risk factors

	Median treatment cost per episode ($)			Treatment period (days)			Mortality rate (%)
Risk factors	Outpatient episodes	GW episodes	ICU episodes	Outpatient episodes	GW episodes	ICU episodes	GW episodes	ICU episodes
Total	346	4824	12,728	7	14	24	12%	30%
Sex
Male	356	4791	12,518	7	14	22	12%	30%
Female	330	4872	12,792	7	15	27	11%	31%
Age group
65–74 years	353	4391	19,485	8	12	34	7%	20%
75–84 years	352	4778	11,098	7	14	17	10%	32%
≥ 85 years	323	5162	13,105	6	16	28	16%	39%
Comorbidities
Diabetes mellitus	384	4878	10,035	8	15	21	10%	30%
COPD	355	4836	11,238	8	14	18	10%	39%
Liver function failure	338	4738	10,029	8	15	21	12%	37%
Dementia	320	5567	21,078	7	17	60	19%	0%
Dialysis	732	6389	23,136	6	15	37	15%	14%
Rheumatism	412	4910	20,673	8	15	34	10%	50%
Cancer	377	4528	8064	8	14	14	15%	50%
Prescriptions during previous 6 months
Oral antibiotics	375	4821	11,218	8	14	20	13%	46%
Inhaled steroids	346	4622	11,388	7	13	22	8%	30%
ACE-I	298	5124	8778	7	15	19	11%	13%
Statins	352	4705	11,372	7	14	20	7%	21%

GW general ward, ICU intensive care unit, COPD chronic obstructive pulmonary disease, ACE-I angiotensin-converting enzyme inhibitors

ISSN: 2200-6133